Riedel Norbert G
SEC-identified person · CIK 1161662 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Eton Pharmaceuticals, Inc. ETON | Director | filed 2018–2026 |
| Jazz Pharmaceuticals plc JAZZ | Director | filed 2013–2026 |
| Cerevel Therapeutics Holdings, Inc. CERF | Director | filed 2020–2024 |
| Aptinyx Inc. APTX | Director · EXECUTIVE CHAIRMAN OF THE BOD | filed 2018–2023 |
| Ariad Pharmaceuticals INC ARIA | Director | filed 2011–2017 |
| Baxter International INC NYSE: BAX | Corporate Vice President | filed 2006–2013 |
| Oscient Pharmaceuticals Corp OSCI | Director | filed 2006–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.